Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cd

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    565 result(s) found for: Cd. Displaying page 1 of 29.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2018-001382-17 Sponsor Protocol Number: RP1610 Start Date*: 2018-10-30
    Sponsor Name:Alimentiv Inc
    Full Title: Stopping Aminosalicylate Therapy in Inactive Crohn’s Disease (STATIC) Study: A Randomized, Open-label, Non-inferiority Trial
    Medical condition: Inactive Crohn’s Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-001925-18 Sponsor Protocol Number: GED-0301-CD-002 Start Date*: 2016-02-24
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of mongersen (GED-0301) for the treatment of subjects with active Crohn’s disease.
    Medical condition: Active Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000016693 10021315 Ileitis terminal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) SE (Completed) SK (Completed) LV (Prematurely Ended) EE (Prematurely Ended) DE (Prematurely Ended) PT (Prematurely Ended) HU (Completed) CZ (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) BE (Completed) NO (Completed) BG (Prematurely Ended) GR (Completed) HR (Prematurely Ended) FI (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001050-41 Sponsor Protocol Number: RP1202 Start Date*: 2015-06-12
    Sponsor Name:Robarts Clinical Trials
    Full Title: A Cluster Randomized Controlled Trial of an Enhanced Treatment Algorithm for the Management of Crohn's Disease
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10011402 Crohn's disease (colon) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003359-43 Sponsor Protocol Number: B7981007 Start Date*: 2018-05-24
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 As Induction And Open Label Extension Treatmen...
    Medical condition: Moderate To Severe Crohn’s Disease (CD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) DE (Completed) SK (Completed) AT (Completed) PL (Completed) HU (Completed) ES (Completed) CZ (Completed) BE (Completed) HR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004295-55 Sponsor Protocol Number: RPC01-3204 Start Date*: 2018-03-08
    Sponsor Name:Celgene International II Sàrl
    Full Title: A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease
    Medical condition: Moderately to Severely Active Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Ongoing) SK (Trial now transitioned) LV (Ongoing) LT (Completed) CZ (Trial now transitioned) FR (Trial now transitioned) SI (Completed) AT (Completed) BG (Trial now transitioned) DE (Trial now transitioned) GR (Completed) ES (Ongoing) SE (Ongoing) NL (Ongoing) PL (Ongoing) BE (Completed) IE (Trial now transitioned) GB (Not Authorised) FI (Ongoing) DK (Completed) PT (Trial now transitioned) HR (Ongoing) IT (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001240-35 Sponsor Protocol Number: M14-433 Start Date*: 2018-04-17
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who H...
    Medical condition: Crohn's Disease (CD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) SE (Completed) DE (Completed) AT (Completed) PT (Completed) BE (Completed) IE (Completed) GB (GB - no longer in EU/EEA) LV (Completed) HU (Completed) NL (Completed) PL (Completed) DK (Completed) LT (Completed) EE (Completed) ES (Completed) BG (Completed) HR (Completed) SI (Completed) FR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-001226-18 Sponsor Protocol Number: M14-431 Start Date*: 2018-04-17
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who H...
    Medical condition: Crohn's Disease (CD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) SE (Completed) DK (Completed) AT (Completed) PT (Completed) BE (Completed) IE (Completed) GB (GB - no longer in EU/EEA) LV (Completed) HU (Completed) DE (Completed) PL (Completed) CZ (Completed) LT (Completed) EE (Completed) ES (Completed) BG (Completed) SI (Completed) HR (Ongoing) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2021-005019-30 Sponsor Protocol Number: IM047-023 Start Date*: 2022-12-09
    Sponsor Name:Celgene International II Sarl
    Full Title: A Phase 2/3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Participants with Moderately...
    Medical condition: Moderately to Severely Active Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) HU (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000576-29 Sponsor Protocol Number: SHP647-306 Start Date*: Information not available in EudraCT
    Sponsor Name:Shire Human Genetic Therapies, Inc.
    Full Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 306)
    Medical condition: Crohn’s disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10011402 Crohn's disease (colon) LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) BE (Completed) HU (Completed) SK (Completed) ES (Prematurely Ended) PT (Completed) EE (Completed) BG (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2018-004614-18 Sponsor Protocol Number: I6T-MC-AMAM Start Date*: 2019-07-10
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Acti...
    Medical condition: moderately to severely active Crohn’s disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed) FR (Ongoing) GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) ES (Completed) PL (Completed) DK (Ongoing) BE (Completed) SK (Completed) LT (Completed) CZ (Completed) LV (Completed) HR (Completed) IT (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-000811-29 Sponsor Protocol Number: I6T-MC-AMAY Start Date*: 2023-08-16
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Multicenter, Randomized, Platform Study of p19 Inhibition of the IL-23 Pathway to Establish Efficacy in Pediatric Crohn’s Disease (MACARONI-23)
    Medical condition: Clinical Study to Evaluate Mirikizumab in Pediatric Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NO (Ongoing) BE (Ongoing) ES (Ongoing) IT (Ongoing) AT (Ongoing) PT (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023347-14 Sponsor Protocol Number: 2010-10 Start Date*: 2011-03-02
    Sponsor Name:Gastroenterology CHC Liege
    Full Title: Treatment of Crohn’s disease-associated refractory diarrhoea with octreotide LAR An open pilot study
    Medical condition: Crohn Disease refractory diarrhoea
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066533 Diarrhea recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001225-41 Sponsor Protocol Number: M14-430 Start Date*: 2018-04-17
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo- Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Comp...
    Medical condition: Crohn's Disease (CD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Trial now transitioned) DK (Trial now transitioned) AT (Trial now transitioned) DE (Ongoing) SE (Trial now transitioned) LV (Ongoing) GB (GB - no longer in EU/EEA) PT (Ongoing) FR (Trial now transitioned) HU (Ongoing) NL (Trial now transitioned) IE (Completed) LT (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) BG (Completed) BE (Trial now transitioned) SI (Completed) HR (Ongoing) IT (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000482-31 Sponsor Protocol Number: MLN0002SC-3030 Start Date*: 2016-01-22
    Sponsor Name:Takeda Development Centre Europe, Ltd.
    Full Title: A Phase 3b Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab Subcutaneous in Subjects with Ulcerative Colitis and Crohn’s Disease
    Medical condition: Ulcerative Colitis Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    20.1 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) NL (Ongoing) BG (Completed) GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) SE (Completed) DK (Completed) LT (Completed) ES (Prematurely Ended) HU (Completed) RO (Ongoing) HR (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001087-30 Sponsor Protocol Number: CT-P13_3.8 Start Date*: 2019-07-25
    Sponsor Name:Celltrion, Inc
    Full Title: A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients With Moderat...
    Medical condition: Moderately to Severely Active Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) CZ (Completed) SK (Completed) FR (Completed) PL (Completed) DE (Completed) GR (Completed) HU (Completed) ES (Completed) AT (Completed) BG (Completed) HR (Completed) IT (Ongoing) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-000575-88 Sponsor Protocol Number: SHP647-305 Start Date*: 2019-02-28
    Sponsor Name:Shire Human Genetic Therapies, Inc.
    Full Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 305)
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) AT (Completed) LT (Completed) CZ (Prematurely Ended) DE (Completed) PL (Completed) HR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2016-002204-84 Sponsor Protocol Number: I6T-MC-AMAG Start Date*: 2017-02-01
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo- Controlled Study of LY3074828 in Subjects with Active Crohn’s Disease (SERENITY)
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) HU (Completed) AT (Completed) NL (Completed) PL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004301-31 Sponsor Protocol Number: MLN0002-3025 Start Date*: 2021-06-25
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects with Moderately to Severely Active Crohn’s Dise...
    Medical condition: Moderately to severely active Crohn’s disease (CD)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10058815 Crohn's disease acute episode LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LT (Completed) CZ (Ongoing) SK (Prematurely Ended) HU (Ongoing) IT (Ongoing) ES (Prematurely Ended) HR (Ongoing) PL (Ongoing) BE (Ongoing) Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2014-003824-36 Sponsor Protocol Number: GA29144 Start Date*: 2015-08-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB AS AN INDUCTION AND MAINTENANCE TREATMENT FOR PATIENTS WITH MODERATE...
    Medical condition: Crohn`s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) EE (Completed) LT (Completed) LV (Completed) HU (Completed) DE (Prematurely Ended) ES (Ongoing) CZ (Completed) NL (Completed) AT (Completed) SK (Completed) BE (Completed) FR (Ongoing) HR (Completed) RO (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004775-40 Sponsor Protocol Number: APD334-202EU Start Date*: 2021-05-11
    Sponsor Name:Arena Pharmaceuticals Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) DE (Ongoing) DK (Ongoing) SK (Ongoing) LT (Ongoing) LV (Completed) HU (Ongoing) CZ (Ongoing) PT (Prematurely Ended) NO (Completed) BE (Ongoing) BG (Ongoing) ES (Ongoing) HR (Ongoing) IT (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 04:33:08 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA